Introduction
of the general population worldwide and represents a spectrum of hepatic dysfunction linked to obesity, insulin resistance and metabolic syndrome [1] [2] [3] [4] . NAFLD exhibits dysregulation of hepatic lipid metabolism and accelerates the accumulation of triglycerides and cholesterol in hepatocytes [5] . The excess accu--matory conditions and together with the dysfunction of adipose tissue exacerbates hepatic steatosis [6, 7] . Hepatic steatosis is a leading cause of nonalcoholic steatohepatitis (NASH) and can Multiple important pathogenic drivers have been implicated in the initiation and progression of hepatic steatosis, such as lipotoxicity, oxidative stress and immune cell infiltration [8, 9] . However, there is no well-established pharmacological approach for the treatment of hepatic steatosis [10, 11] . Thus, studies identifying novel therapeutic targets and NAFLD treatments are urgently needed.
AMP-activated protein kinase (AMPK) is a conserved serine/threonine protein kinase that is activated by low cellular energy status. The activation of AMPK restores cellular energy homeostasis by triggering catalytic processes (eg, glucose and fatty acid oxidation) to stimulate ATP generation and inhibits anabolic processes (eg, gluconeogenesis and fatty acid synthesis) to decrease ATP consumption [12] . Due to its central role in the control of multiple metabolic pathways, AMPK has become a potential therapeutic target for treating type 2 diabetes (T2D), insulin resistance, obesity and NAFLD . AMPK exists as a heterotrimer consisting of a highly conmammals, each subunit is encoded by several distinct genes [16] . There is differential expression of the complexes, and the expression profile is unique in specific tissues or subcellular locations.
- [12] . The mammalian AMPK heterotrimers are activated in the following three complementary ways: (1) phosphorylation of the connumber may be different in other species) by upstream kinases dependent protein kinase kinases and transforming growth --subunit, which leads to conformational changes and induces Thr172 phosphorylation by upstream kinases and concurrent inhibition of Thr172 dephosphorylation [17] [18] [19] . Numerous observations obtained using agents such as metformin and berberine to deplete intracellular ATP or a pharmacological activator indicated that AMPK activation decreases the hepatic triglyceride (TG) content by decreasing de novo lipogenesis, promoting fatty acid oxidation and regulating inflammation [20] [21] [22] . Additionally, in a genetic mouse hepatic steatosis when the mice were fed a high fructose diet, -sue increased HFD-induced hepatic lipid accumulation .
activation of AMPK could provide a new strategy for the management of NAFLD. Given the potential therapeutic application of AMPK activators, the feasibility of developing AMPK activators has begun to emerge [25] tified by Abbott laboratories in 2006, binds to the allosteric [20, 25, 26] . Several structurally diverse compounds such as 991, PF-06409577 and PF-249 have also been shown to bind to this allosteric pocket [27] [28] [29] screening. These molecules activate AMPK by antagonizing . -pound 1 in vitro ( Figure S1 ). 1 50 poor plasma stability in vivo. Herein, we present our efforts to optimize compound 1 -tuted pyrazolone derivatives as novel AMPK activators.
Materials and methods

Chemistry
The experimental procedures and characterization of all Different recombinant AMPK protein construction, expression AMPK subunit and constructed in a pET28b vector, the difpET28b vector and expressed and purified as previously described .
Measurement of AMPK activity in vitro --tion of compounds by AMPK were detected using the STK ® KinEASE™-STK1 Kit as previously described [41] . The activation fold change was compared to the baseline activity of assay, the AMPK activity and the activation of compounds by AMPK were detected mainly as previously described except the reactions were conducted in 96-well V-shape plates with 2 , 0.8 mmol/L DTT, 2% DMSO (compounds P] ATP per reaction). The reac-PO 4 . We H PO 4 counting cocktail (PerkinElmer) into each well before detecting the radioactivity on a Wallac Microbeta plate counter .
Measurement of lipid synthesis in the HepG2 cell line
A total of 4×10 4 HepG2 cells were seeded per well in whitewalled 96-well plates containing HG-DMEM supplemented Perkin Elmer) was added to each well and incubated for 4 h.
replaced with 0.25 mol/L NaOH. The protein concentration was then measured, and Microscint 20 was added to wells. The radioactivity incorporated into the lipids was monitored using a Wallac Microbeta plate reader and corrected for protein concentration [42] .
Adenovirus infection and measurement of lipid synthesis USA). We seeded 4×10 4 HepG2 cells per well in white-walled 96-well plates with HG-DMEM supplemented with 10% -medium was replaced with HG-DMEM supplemented with -ments were initiated.
L6 myotube culture and 2-deoxy -[
3 H]-D-glucose uptake measurements We seeded 4×10 5 myoblast cells per well in 24-well plates con--days after differentiation, the L6 myotube cells were used for compound treatment and subsequent glucose uptake mea-
followed by incubation with 2-deoxy-[ H]-D-glucose for 15
0.25 mol/L NaOH before the radioactivity was counted .
Statistical analysis
The results are presented as the mean±SEM. Differences between the two groups were analyzed using paired Student's t-tests. The differences among multiple groups were compared by one-way ANOVA, followed by LSD comparison. P
Results
Structure and activity relationship of compound 1 derivatives Due to the instability of the ester group in compound 1, we initially prepared compounds 16-25 with either an alkyl amine (16-20, 23, 25) or an arylamine (21, 22, 24) instead of an ester group. The activities of these compounds are summarized in Table 1 . Among these pyrazolones, compounds 16 and 21-24 the other compounds showed a range of AMPK activation -lones showed any activity (21, 22 and 24), but the alkylamine pyralozones remained active. The trends showed that larger 17, 18, 19 particular, compounds with a phenyl-substituted ring showed better activity. Moreover, an electron-donating group on the phenyl ring (25) enhanced activity, and an electron withdrawing substituent reduced activity (23).
the right-hand side benzene ring subunit of compound 1 was synthesized. We chose electron-donating groups from the library for the phenyl ring compound. The activities of these compounds toward AMPK are summarized in decreased activity compared to compound 29.
We next studied the middle of the structure by keeping the -pounds 46 and 47 were designed to determine the skeleton of the piperidine pyrazolone, while 48 and 49 were designed to determine substituents and sites in the middle benzene 47 had a methyl group on the pyrazolone ring N atom, and its activ-50 compounds also generally retained their activity. in vitro metabolism studies of compound 29 in human, monkey, dog, mouse and rat liver microsomes, compound After synthesizing the potent activator compound 29, we 
29
-29 activated -A769662 and AMP activated AMPK dose-dependently in the 29 (Fig-29 - The treatment had no effect on the ratio of AMP/ATP and of AMPK decreases the lipid content in hepatocytes through inhibition of de novo lipogenesis (DNL) and by increasing fatty 29 1c ( Figure S2 ) and inhibited the accumulation of triglycerides in a dose-dependent manner in HepG2 cells ( Figure 4D ). 
29-29
Discussion AMPK, an energy sensor involved in a combination of inhibited anabolic pathways and stimulated catabolic pathways, has been as diabetes and NAFLD [12, 22, 24, 44] activators could be divided into three classes: activators bind to activators interact with the ADaM domain such as A769662 subunit . Here, we report a novel AMPK activator 29 29 activated the it to activate AMPK heterotrimers with non-selective properfor AMPK allosteric activation, and more work to identify the binding site will be required for us to gain insights into the 29. C29 treatment in vivo potentially increased phosphorylation of hepatic AMPK after a 5-week dosing period ( Figure 6 ). The decrease in plasma and liver lipid levels can be explained by the decreased synthesis of the skeletal muscle is associated with glucose consumption.
AMPK activation in hepatocytes involves
that mediate AMPK activation in skeletal muscle and induce glucose uptake, which lowers glucose levels in rodents and non-human primates . Despite maintaining an obvious glucose uptake in L6 myotubes in an AMPK-dependent path-29 exhibited a slight ability to improve glucose tolerance in ob/ob mice after chronic dosing. This effect may be consistent with the poor distribution and weak acti-29 29 for glucose lowering in vivo -vious studies reported that chronic systemic AMPK activation could induce cardiac hypertrophy in a cardiac glycogendependent or glycogen-independent mechanism . We found no adverse effects (including the activity of creatine 29 29 does not impact cardiac function (data not shown).
tives as direct non-selective activators of AMPK heterotrimers and the kinase domain. After initial structural modification of the right ester group to an amide and optimization of the left side and the linking part of compound 1 to improve its potency and in vitro 29 was selected as a typical compound that stimulated phosphorylation of AMPK and C29 also inhibited lipid accumulation in hepatocytes and improved lipid metabolism both in the liver and in the plasma of ob/ob 29 is a novel allosteric AMPK activator and has potential applications in the treatment of NAFLD and associated metabolic disorders. 
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